An artificial intelligence-assisted diagnostic platform for rapid near-patient hematology.

Neta Bachar¹, Dana Benbassat¹, David Brailovsky¹, Yochay Eshel¹, Dan Glück¹, Daniel Levner¹, Sarah Levy¹, Sharon Pecker¹, Evgeny Yurkovsky¹, Amir Zait¹, Cordelia Sever², Alexander Kratz^3,4, Carlo Brugnara^5,6

¹S.D. Sight Diagnostics LTD, Tel Aviv-Jaffa, Israel.

²TriCore Reference Laboratories, Albuquerque, New Mexico, USA.

³Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, New York, New York, USA.

⁴New York-Presbyterian Hospital, New York, New York, USA.

⁵Department of Laboratory Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.

⁶Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.

PubMed PMC DOI PDF

Abstract

Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19-parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) an…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.